Effectiveness of medical therapy for treatment of idiopathic frequent premature ventricular complexes.


Journal

Journal of cardiovascular electrophysiology
ISSN: 1540-8167
Titre abrégé: J Cardiovasc Electrophysiol
Pays: United States
ID NLM: 9010756

Informations de publication

Date de publication:
08 2021
Historique:
revised: 20 05 2021
received: 01 03 2021
accepted: 21 06 2021
pubmed: 4 7 2021
medline: 21 10 2021
entrez: 3 7 2021
Statut: ppublish

Résumé

The relative effectiveness of medical therapy compared with a conservative approach of monitoring in patients with idiopathic frequent premature ventricular complexes (PVCs) is uncertain. We evaluated the effectiveness of medical versus conservative therapy for frequent PVCs. Patients with frequent PVCs (≥5%) were prospectively enrolled in this cohort study between 2016 and 2020. In patients with normal cardiac function and no structural heart disease, those receiving medical therapy were compared with controls without therapy. Patients were followed longitudinally for change in PVC burden and with serial echocardiography. Overall, 120 patients met inclusion criteria (mean: 56.5 ± 14.6 years, 54.2% female) with 53 on beta-blockers or calcium channel blockers (BBs/CCBs), 27 on Class I or III antiarrhythmic drugs (AADs), and 40 patients treated conservatively. Median initial PVC burden ranged from 15.5% to 20.6%. The median relative reduction of PVCs was 32.7%, 30.5%, and 81.3%, in the conservative therapy, BBs/CCBs, and AADs cohorts, respectively. AADs had greater PVC reduction compared with BBs/CCBs (p = 0.017) and conservative therapy (p = 0.045). PVC reduction to <1% was comparable across groups at 35.0%, 17.0%, 33.3%, respectively. Four patients (4/120, 3.3%) developed left ventricular dysfunction. Rates of adverse drug reactions and medication discontinuation were similar between groups, with no serious adverse events noted. In patients with idiopathic frequent PVCs, BB, and CCB have limited effectiveness in PVC reduction. Class I and III AADs have superior effectiveness for medical therapy in symptomatic patients, but only achieved complete PVC resolution suppression in one-third of patients.

Identifiants

pubmed: 34216056
doi: 10.1111/jce.15150
doi:

Substances chimiques

Anti-Arrhythmia Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2246-2253

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© 2021 Wiley Periodicals LLC.

Références

Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Circulation. 2018;138(13):e272-e391.
Latchamsetty R, Bogun F. Premature ventricular complex-induced cardiomyopathy. JACC Clin Electrophysiol. 2019;5(5):537-550.
Baman TS, Lange DC, Ilg KJ, et al. Relationship between burden of premature ventricular complexes and left ventricular function. Heart Rhythm. 2010;7(7):865-869.
Latchamsetty R, Yokokawa M, Morady F, et al. Multicenter outcomes for catheter ablation of idiopathic premature ventricular complexes. JACC Clin Electrophysiol. 2015;1(3):116-123.
Zhong L, Lee YH, Huang XM, et al. Relative efficacy of catheter ablation vs antiarrhythmic drugs in treating premature ventricular contractions: A single-center retrospective study. Heart Rhythm. 2014;11(2):187-193.
Gorenek B, Fisher JD, Kudaiberdieva G, et al. Premature ventricular complexes: Diagnostic and therapeutic considerations in clinical practice: A state-of-the-art review by the american college of cardiology electrophysiology council. J Interv Card Electrophysiol. 2020;57(1):5-26.
Myburgh DP, Smith R, Diamond TH, Faitelson HL, Sommers DK. A comparison of the efficacy of sotalol and nadolol in the suppression of ventricular ectopic beats. SAMJ. 1983;63(8):263-265.
Chandraratna PAN. Comparison of acebutolol with propranolol, quinidine, and placebo: Results of three multicenter arrhythmia trials. Am Heart J. 1985;109(5 PART 2):1198-1204.
Kubac G, Klinke WP, Grace M. Randomized double blind trial comparing sotalol and propranolol in chronic ventricular arrhythmia. Can J Cardiol. 1988;4(7):355-359.
Deedwania. Sotalol is more powerful than propranolol in suppressing complex ventricular arrhythmias. J Cardiovasc Pharmacol Ther. 1997;2(4):259-272.
Stec S, Sikorska A, Zaborska B, Kryński T, Szymot J, Kułakowski P. Benign symptomatic premature ventricular complexes: short− and long−term efficacy of antiarrhythmic drugs and radiofrequency ablation. Kardiol Pol. 2012;70:351-358.
Lee AKY, Andrade J, Hawkins NM, et al. Outcomes of untreated frequent premature ventricular complexes with normal left ventricular function. Heart. 2019;105(18):1408-1413.
Mountantonakis SE, Frankel DS, Gerstenfeld EP, et al. Reversal of outflow tract ventricular premature depolarization-induced cardiomyopathy with ablation: effect of residual arrhythmia burden and preexisting cardiomyopathy on outcome. Heart Rhythm. 2011;8:1608-1614.
Williams CB, Andrade JG, Hawkins NM, et al. Establishing reference ranges for ambulatory electrocardiography parameters: meta-analysis. Heart. 2020;106:1732-1739.
Betensky BP, Park RE, Marchlinski FE, et al. The V2 transition ratio. J Am Coll Cardiol. 2011;57(22):2255-2262.
Anderson RD, Kumar S, Parameswaran R, et al. Differentiating right- and left-sided outflow tract ventricular arrhythmias: classical ECG signatures and prediction algorithms. Circ Arrhythm Electrophysiol. 2019;12:12.
Takumi Y. Twelve-lead electrocardiographic localization of idiopathic premature ventricular contraction origins. J Cardiovasc Electrophysiol. 2019;30:2603-2617.
Kostis JB, McCrone K, Moreyra AE, et al. Premature ventricular complexes in the absence of identifiable heart disease. Circulation. 1981;63(6):1351-1356.
Hamon D, Swid MA, Rajendran PS, et al. Premature ventricular contraction diurnal profiles predict distinct clinical characteristics and beta-blocker responses. J Cardiovasc Electrophysiol. 2019;30(6):836-843.
Ling Z, Liu Z, Su L, et al. Radiofrequency ablation versus antiarrhythmic medication for treatment of ventricular premature beats from the right ventricular outflow tract prospective randomized study. Circ Arrhythm Electrophysiol. 2014;7(2):237-243.
Krittayaphong R, Bhuripanyo K, Punlee K, Kangkagate C, Chaithiraphan S. Effect of atenolol on symptomatic ventricular arrhythmia without structural heart disease: a randomized placebo-controlled study. Am Heart J. 2002;144(6):10.

Auteurs

Jacky K K Tang (JKK)

Heart Rhythm Services, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.

Jason G Andrade (JG)

Heart Rhythm Services, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.
Centre for Cardiovascular Innovation, University of British Columbia, Vancouver, British Columbia, Canada.

Nathaniel M Hawkins (NM)

Heart Rhythm Services, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.
Centre for Cardiovascular Innovation, University of British Columbia, Vancouver, British Columbia, Canada.

Zachary W Laksman (ZW)

Heart Rhythm Services, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.
Centre for Cardiovascular Innovation, University of British Columbia, Vancouver, British Columbia, Canada.

Andrew D Krahn (AD)

Heart Rhythm Services, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.
Centre for Cardiovascular Innovation, University of British Columbia, Vancouver, British Columbia, Canada.

Matthew T Bennett (MT)

Heart Rhythm Services, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.
Centre for Cardiovascular Innovation, University of British Columbia, Vancouver, British Columbia, Canada.

Brett Heilbron (B)

Heart Rhythm Services, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.

Santabhanu Chakrabarti (S)

Heart Rhythm Services, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.

John A Yeung-Lai-Wah (JA)

Heart Rhythm Services, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.

Marc W Deyell (MW)

Heart Rhythm Services, Division of Cardiology, University of British Columbia, Vancouver, British Columbia, Canada.
Centre for Cardiovascular Innovation, University of British Columbia, Vancouver, British Columbia, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH